The last decade has witnessed unprecedented advances in the treatment of multiple sclerosis (MS).  Nine drugs have been approved by the Food and Drug Administration (FDA) for the management of relapsing remitting (RR) MS.  A number of other promising agents are currently under review or are being tested in Phase 3 trials.  These disease modifying therapies (DMTs) have been shown to prevent clinical exacerbations and new MRI lesion formation with varying degrees of efficacy. Each is designed to alter or suppress the autoimmune response that is believed to drive MS pathogenesis.    While the introduction of DMT has improved the clinical outlook for patients in the RR phase of disease, significant challenges remain. Future priorities include the development of effective DMT for individuals with progressive disease, the introduction of neuroprotective and neuroregenerating agents and the discovery of biomarkers that facilitate customized therapy.

Current status and future directions of disease modifying therapy in multiple sclerosis

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.